|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 282.00 GBX | -1.30% |
|
+3.79% | +19.49% |
| 01-16 | BofA cuts British Land; RBC raises Gym Group | AN |
| 01-08 | Marks & Spencer has "record" Christmas as food sales offset clothing | AN |
John C. Martin is on the board of Sarepta Therapeutics, Inc. and 5 other companies. In the past Dr. Martin was Chairman at Gilead Sciences, Inc., President of The International Society for Antiviral Research, Principal at Bristol Myers Squibb Co., Council Member at National Institute of Allergy & Infectious Diseases, Director at California Healthcare Institute, Chairman at The Bay Area Bioscience Association, Principal at Syntex Corp., Member of National Academy of Engineering and Member of The Presidential Advisory Council on HIV. Dr. Martin received a doctorate from The University of Chicago, an MBA from Golden Gate University and an undergraduate degree from Purdue University.
View full profile
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Select your edition
All financial news and data tailored to specific country editions
